Altimmune presents new data on the effect of pemvidutide on inflammatory lipids in subjects with metabolic dysfunction-associated steatotic liver disease (masld) at the liver meeting® 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
ALT Ratings Summary
ALT Quant Ranking